Molecular characterization of ESR1 variants in breast cancer

[1]  Y. Bang,et al.  Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. , 2020, The Lancet. Oncology.

[2]  R. Schiff,et al.  Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance , 2020, bioRxiv.

[3]  A. Shaw,et al.  TEMPORARY REMOVAL: Updated overall survival and final progression-free survival data for patients with treatment-naïve advanced ALK-positive non-small-cell lung cancer in the ALEX study. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  E. Sokol,et al.  The genomic landscape of metastatic breast cancer: Insights from 11,000 tumors , 2020, PloS one.

[5]  C. Arteaga,et al.  Overcoming Endocrine Resistance in Breast Cancer. , 2020, Cancer cell.

[6]  A. Stenzinger,et al.  Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project , 2020, Journal for ImmunoTherapy of Cancer.

[7]  I. Barshack,et al.  ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis , 2020, Breast Cancer Research.

[8]  P. De,et al.  ER+ metastatic breast cancer: past, present, and a prescription for an apoptosis-targeted future. , 2019, American journal of cancer research.

[9]  Ahmedin Jemal,et al.  Breast cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.

[10]  C. Antonescu,et al.  Uterine Tumor Resembling Ovarian Sex Cord Tumor: A Distinct Entity Characterized by Recurrent NCOA2/3 Gene Fusions , 2019, The American journal of surgical pathology.

[11]  Rohit Bhargava,et al.  Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer , 2018, Molecular Cancer Research.

[12]  B. Taylor,et al.  The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. , 2018, Cancer cell.

[13]  Sherri,et al.  Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer , 2018, Cell reports.

[14]  Ross A. Hamilton,et al.  Proteomic profiling identifies key coactivators utilized by mutant ERα proteins as potential new therapeutic targets , 2018, Oncogene.

[15]  Funda Meric-Bernstam,et al.  Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children , 2018, The New England journal of medicine.

[16]  Maristela L Onozato,et al.  Expressed Gene Fusions as Frequent Drivers of Poor Outcomes in Hormone Receptor-Positive Breast Cancer. , 2017, Cancer discovery.

[17]  Daniel F. Hayes,et al.  20‐Year Risks of Breast‐Cancer Recurrence after Stopping Endocrine Therapy at 5 Years , 2017, The New England journal of medicine.

[18]  Geet Duggal,et al.  Salmon: fast and bias-aware quantification of transcript expression using dual-phase inference , 2017, Nature Methods.

[19]  G. Hortobagyi,et al.  Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial. , 2016, JAMA oncology.

[20]  M. Dowsett,et al.  Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  M. Ellis,et al.  Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer , 2015, Clinical Cancer Research.

[22]  R. Gelber,et al.  Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  B. Ramaswamy,et al.  Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trial , 2015, npj Breast Cancer.

[24]  M. Ellis,et al.  Mechanisms of aromatase inhibitor resistance , 2015, Nature Reviews Cancer.

[25]  Susan G. Hilsenbeck,et al.  Recurrent ESR1-CCDC170 rearrangements in an aggressive subset of estrogen-receptor positive breast cancers , 2014, Nature Communications.

[26]  David Chen,et al.  ESR1 ligand binding domain mutations in hormone-resistant breast cancer , 2013, Nature Genetics.

[27]  Javed Siddiqui,et al.  Activating ESR1 mutations in hormone-resistant metastatic breast cancer , 2013, Nature Genetics.

[28]  F. Maurer,et al.  The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation , 2003, Proceedings of the National Academy of Sciences of the United States of America.